Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.

Clémentine Boccon-Gibod^{1

2}, Alexis Talbot^{1

2}, Fabien Le Bras^{3

4}, Laurent Frenzel^{5

6}, Bruno Royer^{1

2}, Stephanie Harel^{1

2}, Naelle Lombion^{1

2}, Karim Belhadj^{3

4}, Wendy Cuccuini⁷, Bertrand Arnulf^{1

2}

¹ Immuno-hematology Department, Hôpital Saint-Louis, APHP, Paris, France.
² Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.
³ Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France.
⁴ Mondor Amyloidosis Network, Créteil, France.
⁵ Department of Hematology, Université Paris Descartes, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France.
⁶ Institut Imagine INSERM U1163 and CNRS ERL8654, Université Paris Descartes, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France.
⁷ Department of Cytogenetics, Hôpital Saint-Louis, Paris, France.

No abstract available

Keywords: carfilzomib; relapsed refractory multiple myeloma; t(11;14); venetoclax.

Publication types